Spontaneous correction or reversion of an inherited variant to a normal genetic status in a stem cell that then repopulates the bone marrowwith unaffected cells.
« Back to Glossary IndexNews
Related News
If you asked me for a defining memory of our journey, it might surprise you. Some of my most cherished moments were the long hospital stays — the time I got to spend one-on-one with Hunsley, free from the distractions of the world.
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
Katherine (middle) with 2023's recipient Ana Tabar (left) and FCF CEO Isis Sroka (right) The De Los Santos family first experienced the complexities of Fanconi anemia as they endured the devastating loss of their daughter, Gracie, who passed away from...